ELI LILLY AND CO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and what generic alternatives to ELI LILLY AND CO drugs are available?
ELI LILLY AND CO has seven approved drugs.
There are nineteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and eighty-two patent family members on ELI LILLY AND CO drugs in fifty-six countries and forty-four supplementary protection certificates in eighteen countries.
Summary for ELI LILLY AND CO
| International Patents: | 382 |
| US Patents: | 19 |
| Tradenames: | 10 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for ELI LILLY AND CO: | See patent lawsuits for ELI LILLY AND CO |
| PTAB Cases with ELI LILLY AND CO as petitioner: | See PTAB cases with ELI LILLY AND CO as petitioner |
| PTAB Cases with ELI LILLY AND CO as patent owner: | See PTAB cases with ELI LILLY AND CO as patent owner |
Drugs and US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | 11,045,474 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-003 | May 10, 2022 | RX | Yes | Yes | 11,806,555 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELI LILLY AND CO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,683,235 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,594,358 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,590,213 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for ELI LILLY AND CO Drugs
Supplementary Protection Certificates for ELI LILLY AND CO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | 9/2019 | Austria | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1307 (MITTEILUNG) 20181001 |
| 2288610 | 2017033 | Norway | ⤷ Sign Up | PRODUCT NAME: BARICITINIB OG FARMASOEYTISK; REG. NO/DATE: EU/1/16/1170 20170222 |
| 2379528 | 2019009 | Norway | ⤷ Sign Up | PRODUCT NAME: ABEMACIKLIB ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1307 20180927 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
